Ronald Littlefield
Cardiovascular Disease · Spartanburg, SCNPI 1619935715
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,931 and has fallen 83.4% since, to $321 in 2021. That places this record below the midpoint for cardiovascular disease clinicians in SC, where the typical reported total is $3,855.
Across 286 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$826
- Amarin Pharma, Inc.$396
- Novo Nordisk$364
- Sanofi-aventis U.S. LLC$345
- Lilly USA, LLC$265
- Johnson & Johnson$263
- plus $2K from 16 others
Across 7 payments — averaging $2860.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$15K
- Astrazeneca UK Limited$2K
- Merck$2K
- Kowa Research Institute, Inc.$840
What the payments were for
- Food & beverage$4,127100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 57 | $826 |
| Amarin Pharma, Inc. | 25 | $396 |
| Novo Nordisk | 28 | $364 |
| Sanofi-aventis U.S. LLC | 18 | $345 |
| Lilly USA, LLC | 21 | $265 |
| Johnson & Johnson | 20 | $263 |
| Pfizer | 18 | $220 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $207 |
| Novartis | 15 | $205 |
| Merck | 15 | $202 |
| Arbor Pharmaceuticals, Inc. | 10 | $166 |
| Astellas Pharma US Inc | 9 | $146 |
| AstraZeneca | 10 | $135 |
| GSK | 9 | $127 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| AbbVie(2 entities) | 4 | $58 |
| Sunovion Pharmaceuticals Inc. | 4 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Medtronic | 1 | $13 |
| Mannkind Corporation | 1 | $12 |
How this compares
$4,135 in reported general payments places this provider in the 50th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Other cardiovascular disease in Spartanburg
- David RodakSpartanburg$23K
- Nalin SrivastavaSpartanburg$15K
- Alejandro LopezSpartanburg$12K
- Joseph MobleySpartanburg$10K
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- Gregory EavesAiken$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.